The hemodynamic effects of quinapril, a novel nonsulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor, were assessed in 10 patients with mild-to-moderate essential hypertension. Compared with placebo, quinapril (20 mg) administered twice daily for 4 weeks significantly lowered blood pressure by decreasing total peripheral resistance without producing tachycardia, an increase in cardiac output, or a rise in plasma catecholamines. Quinapril significantly reduced renal, but not forearm, vascular resistance. Renal blood flow, glomerular filtration rate, and filtration fraction remained unchanged. Left ventricular wall stress was markedly reduced by quinapril, but during the relatively short treatment period, only a nonsignificant trend toward reduction in left ventricular mass was observed. These findings suggest that quinapril is an effective antihypertensive agent that lowers peripheral resistance without increasing cardiac output or disturbing autoregulation of renal hemodynamics.
tend to result in a chronic depression in cardiac output, particularly during exercise,' and may lead to less physical endurance during severe work loads.5' In contrast, a-adrenoreceptor blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors reduce vascular resistance and maintain blood flow,8-'4 but the degree of counteracting reflex tachycardia and increase in cardiac output varies widely.
It is likely that the blood pressure lowering effect of ACE inhibitors is mediated largely by withdrawal of the vasopressor influences of angiotensin 11, 1516 although other mechanisms such as bradykinin potentiation may participate.
Both angiotensin II withdrawal and bradykinin increase would result in dilation of the arteriolar resistance vessels. Quinapril hydrochloride (C1-906) is a new potent, orally active, nonsulfhydryl, nonpeptide ACE inhibitor developed for the treatment of hypertension and congestive heart failure. Quinapril is converted in vivo to its active metabolite, quinaprilat, which is primarily responsible for its potent ACE inhibition. Clinical studies indicate that quinapril is an effective antihypertensive agent when administered once or twice daily. The acute hemodynamic effects of quinapril have been studied in patients with congestive cardiac failure.' However, there is little information on the chronic hemodynamic effects of quinapril in patients with hypertension. Therefore, the aim of the 42 Gupta et al. present study was to compare the hemodynamic effects of quinapril with placebo during long-term (4 weeks) treatment of patients with mild-to-moderate essential hypertension in a double-blind, randomized crossover design.
MATERIAL AND METHODS
Patients. Ten Issaquah, Wash.) . This technique has previously been described in detail and evaluated in our laboratory.2' The left arm was supported above heart level, and the strain gauge placed around the forearm, approximately 7 cm below the olecranon. Hand blood flow was arrested by a pediatric-sized cuff inflated to suprasystolic pressure at the wrist 60 seconds before FBF determinations. A second cuff on the arm was subsequently inflated to 40 to 50 mm Hg for 10 to 15 seconds and deflated for 5 seconds or more before the next measurement. Forearm blood flow (m1/100 ml forearm volume per minute) was calculated from the mean vertical deflection per minute on the tracings divided by the 1% electrical calibration signal. Forearm vascular resistance (FVR) was calculated as mean arterial blood pressure (MAP) determined during the procedure divided by FBF.
After measuring baseline blood pressure, heart rate, and FBF, the morning dose of medication (quinapril or placebo) was given with 100 ml water. Thereafter, blood pressure, heart rate, and FBF were measured every 1/2 hour throughout, and hemodynamic profiling was done 2 to 4 hours after the medication was administered. Clinical studies in patients with hypertension have demonstrated that peak change in diastolic blood pressure following quinapril administration occurs at 2 to 4 hours after administration of the dose (Parke-Davis, data on file). Therefore this time frame was chosen to determine peak hemodynamic and blood pressure changes after quinapril administration.
Cardiac output was measured 3 hours after dose administration by an echocardiographic Doppler VOLUME 48 NUMBER 1 Table I . Blood pressure, heart rate, forearm blood flow, and forearm vascular resistance for subjects in the supine position for 4 hours after taking the study medication at 8 AM Data are mean values ± SE (n = 10). *p < 0.01; tp < 0.001; tp < 0.05 (quinapril versus placebo).
technique utilizing an ATL Ultramark IV (Bellevue, Wash.). This method has previously been validated against dye dilution in our laboratory.' Twodimensional images of the aortic root were recorded in the long-axis view by use of a 2.25 MHz transducer. The aortic root diameter was measured from the twodimensional image at the level of the aortic leaflets during mid-systole and the aortic crosszsectional area was calculated. Aortic outflow measurements were obtained from the suprasternal notch with a continuous wave Doppler transmitter operating at 3.0 MHz. The cardiac output and stroke volume measurements were calculated by use of a computer-interfaced digitizing tablet and Doppler analysis program (Freeland Medical Systems, Indianapolis, Ind.). The average of eight consecutive cardiac cycles was taken, and only those Doppler recordings that showed maximal flow velocities and exhibited the "cleanest" envelopes were chosen. The flow velocity integral (FVI), or the area under the velocity curve was determined by tracing from the baseline around the maximal velocity curve. Heart rate was measured from the RR interval of the simultaneously recorded ECG. Stroke volume was calculated by use of the formula:
Cardiac output was calculated by multiplying stroke volume (SV) by heart rate. Cardiac index (CI, L/ min/ m2) was calculated as the ratio of cardiac output to body surface area estimated from height and weight in conventional tables. Total peripheral resistance index 65 ± 2 68 ± 3 68 ± 3 Forearm blood flow (m1/100 ml forearm volume/min) Placebo 2.9 ± 0.5 2.5 ± 0.4 2.8 ± 0.4 3.0 ± 0.5 3.2 ± 0.5 3.0 ± 0.5 3.0 ± 0.3 3.2 -± 0.6 3.1 ± 0.5 Quinapril 2.8 ± 0.4 3.4 -± 0.9 3.4 ± 0.9 3.2 -± 0.6 2.9 ±-0.4 3.2 -± 0.5 2.9 ± 0.4 3.1 ± 0.5 3.0 -± 0.4 Statistical analysis. Data are given as mean values -± SE. Blood pressure and vascular resistance were postulated to decrease in subjects receiving quinapril compared with placebo; therefore differences in these variables were tested by one-tailed tests; other differences were tested by two-tailed parametric tests for single or repeated measurements. Correlation coefficients (r) were calculated by use of the least-squares method. A p value less than 0.05 was considered to be the limit for statistical significance.
RESULTS
All the patients entered into the study completed the trial without notable side effects or adverse reaction. The data were tested for an order of treatment effect.
Because this could not be found, further analyses were done by comparing the quinapril with the placebo period, regardless of the order in which they were given.
Blood pressure. Systolic, diastolic, and mean blood pressure were all highly significantly lower on quinapril compared with placebo (p < 0.001, ANOVA). As shown by Table I , blood pressure was significantly lower in subjects receiving quinapril compared with placebo at all time points during the 4-hour period in the Clinical Research Center. Systolic and diastolic blood pressure differences between the two treatments before and 3 hours after the medication was given were 16.4 -± 4.2/9.5 -± 2.6 and 14.0 -± 3.8/10.8 -± 2.3 mm Hg, respectively. Six of the subjects responded with an average decrease in mean blood pressure of more than 10 mm Hg, and two subjects responded with an average decrease in mean blood pressure between 5 and 10 mm Hg. After 4 weeks of twice-daily quinapril therapy, further reductions in blood pressure were not observed during the 4-hour interval after quinapril dosing.
Heart rate and plasma catechokimines. Heart rate did not show any significant difference between the two treatments (Table I) . Plasma norepinephrine drawn 2.5 hours after dose administration averaged 220 It 25 versus 202 -±-16 ng/L for subjects receiving quinapril and placebo, respectively (not significant), and plasma epinephrine was 45 -±-5 versus 47 -± 10 ng /L (not significant).
Forearm blood flow and forearm vascular resistance. Repeated measurement analysis of variance (ANOVA) did not reveal any statistically significant difference for FBF or FVR (Table I ) during placebo and quinapril treatments.
Cardiac index and total peripheral resistance index.
Cardiac function did not change significantly in subjects receiving quinapril treatment compared with placebo (Table II) . Cardiac index averaged 2.51 ± 0.09 versus 2.48 ± 0.09 L/ min/m2 body surface area 3 hours after dose administration on the two treatments, respectively (Fig. 1) . As also shown in Fig. 1 Fig. 2 . Correlation between the differences in total peripheral resistance index (TPRI) and the differences in mean blood pressure (MBP) between treatment with quinapril versus placebo (r = 0.72, p <0.05).
tively (not significant). RBF was therefore statistically unchanged in subjects receiving quinapril (907 ± 36 ml/ min) compared with placebo (896 ± 28 ml/ min).
The filtration fraction was also unchanged. RVR, however, was significantly (p < 0.05) lower in subjects receiving quinapril (12.2 ± 0.8 arbitrary units) compared with placebo (13.6 -± 0.6 arbitrary units), as shown in Fig. 3 . The differences in RVR between the two treatments correlated with the differences in MAP between the two treatments (r = 0.63,p = 0.05). The change in RVR produced by quinapril was similar to the change in TPRI, and changes in the two resistance measurements were almost significantly correlated (r = 0.60, p < 0.07).
DISCUSSION
The present study showed that treatment of hypertensive subjects with quinapril, a novel nonsulfhydryl-ACE inhibitor, effectively lowers blood pressure at doses that do not cause notable side effects. The decrease in blood pressure in subjects receiving long-term quinapril therapy occurred without an increase in plasma catecholamines, reflex tachycardia, or cardiac output, and the decrease in blood pressure was associated with decreased total peripheral resistance. Renal blood flow and glomerular filtration rate were preserved, whereas renal vascular resistance showed a moderate decrease in patients receiving quinapril. Forearm blood flow and vascular resistance were unchanged Although the small decrease in LVM in subjects receiving quinapril was not significant, wall stress was significantly decreased during quinapril treatment (Table II) .
The differences in TPRI between the two treatments correlated significantly with the differences in MAP between the two treatments (Fig. 2) .
Glomerular filtration rate and renal hemodynamics. GFR estimated by endogenous creatinine clearance remained statistically unchanged on quinapril compared with placebo (126 -± 9 versus 127 -± 10 ml/ min per 1.73 m2 body surface area, respectively).
PAH clearance averaged 521 -± 21 versus 519 -± 21 ml/min and hematocrit 42.6 ± 1.2 versus 42.1 -± 1.1 for subjects receiving quinapril and placebo, respec- in patients receiving quinapril compared with placebo. Thus quinapril administered chronically lowers blood pressure by the same mechanism as other ACE inhibitors; that is, it induces a decrease in total and renal vascular resistance without changing cardiac output, 12-l4,2628 The changes induced by quinapril are at variance with the reduced cardiac output and unchanged total peripheral resistance observed on B-adrenergic blockade.' /3-Blockade may worsen' the already depressed cardiac function' in hypertension. As opposed to 13-blockade, vasodilation with, for example, an ACE inhibitor may reverse the established vascular changes in hypertension and may be preferable for the long-term treatment of hypertension.
The In conclusion, we found that the antihypertensive effect of long-term quinapril therapy in patients with hypertension was associated with reduced total peripheral resistance and unchanged cardiac output. No reflex tachycardia or increase in plasma catecholamines was seen. Quinapril reduced renal vascular resistance but preserved renal blood flow and glomerular filtration rate. Forearm blood flow and resistance were unchanged.
